More Widespread use of Ivermectin for the Treatment of COVID-19 Infec-tion could have Saved Many

IF 0.9 Q4 CHEMISTRY, PHYSICAL

Current Organocatalysis Pub Date : 2023-10-10 DOI:10.2174/2213337210666230809141610

Alberto Boretti, Bimal K. Banik

{"title":"More Widespread use of Ivermectin for the Treatment of COVID-19 Infec-tion could have Saved Many","authors":"Alberto Boretti, Bimal K. Banik","doi":"10.2174/2213337210666230809141610","DOIUrl":null,"url":null,"abstract":"Abstract: Here we review the available literature for the specific use of Ivermectin against COVID-19 infection. Currently, 204 works have been published presenting the results of ivermectin use for COVID-19. 156 are peer-reviewed, and 96 are comparing treatment and control groups. Ivermectin was adopted for early treatment in all or part of 22 countries (39 including non-government medical organizations). The 96 studies of Ivermectin for COVID-19 were published by 1,030 scientists, reporting the cases of 135,554 patients in 27 countries. These studies show a statistically significant improvement in mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance. Specifically, improvements recorded were 85%, 62%, and 43% for prophylaxis, early, and late treatment, with confidence intervals (CI) [77-90%], [51-70%], [28-54%] respectively. A 56% improvement was recorded in the 45 randomized controlled trials (RCTs) with CI [41-68%]. A 51% lower mortality was evidenced from 49 studies with CI [37-61%]. In February 2021, when the war on Ivermectin started in the West, it was clear that this drug had positive effects, working in-vivo/in-vitro, and delivering mostly positive results in clinical trials. More widespread use of Ivermectin could have saved many people, and suppression of this drug in many countries that had very high cumulative fatalities per million people has been a very unfortunate occurrence for science.","PeriodicalId":10945,"journal":{"name":"Current Organocatalysis","volume":"89 1","pages":"0"},"PeriodicalIF":0.9000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Organocatalysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2213337210666230809141610","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Here we review the available literature for the specific use of Ivermectin against COVID-19 infection. Currently, 204 works have been published presenting the results of ivermectin use for COVID-19. 156 are peer-reviewed, and 96 are comparing treatment and control groups. Ivermectin was adopted for early treatment in all or part of 22 countries (39 including non-government medical organizations). The 96 studies of Ivermectin for COVID-19 were published by 1,030 scientists, reporting the cases of 135,554 patients in 27 countries. These studies show a statistically significant improvement in mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance. Specifically, improvements recorded were 85%, 62%, and 43% for prophylaxis, early, and late treatment, with confidence intervals (CI) [77-90%], [51-70%], [28-54%] respectively. A 56% improvement was recorded in the 45 randomized controlled trials (RCTs) with CI [41-68%]. A 51% lower mortality was evidenced from 49 studies with CI [37-61%]. In February 2021, when the war on Ivermectin started in the West, it was clear that this drug had positive effects, working in-vivo/in-vitro, and delivering mostly positive results in clinical trials. More widespread use of Ivermectin could have saved many people, and suppression of this drug in many countries that had very high cumulative fatalities per million people has been a very unfortunate occurrence for science.

查看原文本刊更多论文

更广泛地使用伊维菌素治疗COVID-19感染本可以挽救许多人的生命

摘要:本文综述了伊维菌素治疗COVID-19感染的相关文献。目前，已有204篇论文发表，介绍了使用伊维菌素治疗COVID-19的结果。156项是同行评议，96项是比较治疗组和对照组。22个国家(包括非政府医疗组织在内的39个国家)全部或部分采用伊维菌素进行早期治疗。1030名科学家发表了96项关于伊维菌素治疗COVID-19的研究，报告了27个国家135554名患者的病例。这些研究显示在死亡率、通气、ICU、住院、康复、病例和病毒清除率方面有统计学意义的改善。具体而言，记录的预防、早期和晚期治疗的改善分别为85%、62%和43%，置信区间(CI)分别为[77-90%]、[51-70%]、[28-54%]。在45个随机对照试验(RCTs)中，有56%的改善，CI[41-68%]。49项CI研究[37-61%]证明死亡率降低51%。2021年2月，当针对伊维菌素的战争在西方开始时，很明显这种药物具有积极作用，在体内/体外起作用，并在临床试验中取得了积极的结果。更广泛地使用伊维菌素本可以挽救许多人的生命，而在许多每百万人累积死亡率很高的国家，抑制这种药物对科学来说是非常不幸的事情。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Organocatalysis CHEMISTRY, PHYSICAL-

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： Current Organocatalysis is an international peer-reviewed journal that publishes significant research in all areas of organocatalysis. The journal covers organo homogeneous/heterogeneous catalysis, innovative mechanistic studies and kinetics of organocatalytic processes focusing on practical, theoretical and computational aspects. It also includes potential applications of organocatalysts in the fields of drug discovery, synthesis of novel molecules, synthetic method development, green chemistry and chemoenzymatic reactions. This journal also accepts papers on methods, reagents, and mechanism of a synthetic process and technology pertaining to chemistry. Moreover, this journal features full-length/mini review articles within organocatalysis and synthetic chemistry. It is the premier source of organocatalysis and synthetic methods related information for chemists, biologists and engineers pursuing research in industry and academia.